BioEcho develops single-spin and 96-well kits for the isolation of DNA from different starting materials. In contrast to common bind-wash-elute procedures, their proprietary EchoLUTION single-step technology avoids the use of inhibitory or harmful process reagents and does not require washing steps. 90% of the disposal costs are saved as well as more than 40% of the pipet tip consumption costs. The inhibitor-free DNA enables lowered time-to-result in enzyme-dependent genomic analyses such as PCR or NGS.
Nutrition influences the course of MS
Latest NewsNew data prove that propionic acid modulates the intestine-mediated immune regulation in people with multiple sclerosis (MS).
LSP launches US-$600m European life sciences fund
Latest NewsLSP has closed its LSP 6 fund at the $600m hard cap. It is the largest fund ever raised in Europe focused on life sciences ventures.
Biotalys grabs €45m in Series C financing
Latest NewsPest control specialist Biotalys NV has raised an additional €10m to its series C financing bringing its amount to €45m.
Solentim: Aiming for growth
AppointmentsMark Truesdale has been appointed to the position of CEO at Life Sciences company Solentim.
German and UK researchers cut time to sepsis diagnosis
Latest NewsResearchers from German Fraunhofer IGBI have used next-generation sequencing (NGS) to diagnosis sepsis from tiny amounts of microbial DNA in the blood.
Sustainable DNA extraction 70% less plastic, 50% less costs
Sponsored PublicationsBioEcho develops single-spin and 96-well kits for the isolation of DNA from different starting materials. In contrast to common bind-wash-elute procedures, their proprietary EchoLUTION single-step technology avoids the use of inhibitory or harmful process reagents and does not require washing steps. 90% of the disposal costs are saved as well as more than 40% of the pipet tip consumption costs. The inhibitor-free DNA enables lowered time-to-result in enzyme-dependent genomic analyses such as PCR or NGS.
Nordic Nanovector: Provisional head
AppointmentsCTO Lars Nieba has taken over as interim CEO at Nordic Nanovectors after Eduardo Bravo’s sudden departure.
IMI launches €45m call for coronavirus emergency
Latest NewsThe Innovative Medicines Initiative (IMI) has announced a €45m funding for the development of therapeutics and diagnostics to tackle coronavirus outbreaks.
Immunocore Ltd raises US$130m in Series B round
Latest NewsWith the financing led by General Atlantic, the British company wants to expand a novel platform and advance its ImmTAX pipeline to the clinic.
Nouscom: Made official
AppointmentsShe was already serving as interim CEO since Nouscom founder Alfredo Nicosia retired in May 2019. Now, Marina Udiers appointment at the Basel-based immuno-oncology company has been made permanent.